ABN 16 165 160 841 +61 (0) 3 9123 1140 | [email protected] Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 15 Sep 2026 ASX RELEASE AMPLIA AND ANZGOG FINALISE PROTOCOL FOR OVARIAN CANCER CLINICAL TRIAL HIGHLIGHTS • The PRROSE trial will investigate the combination...
Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial
Filed with ASX · · 3 pages · English
Release
Amplia Therapeutics Ltd. on 6ix
In the deck
Earlier from Amplia Therapeutics
- Notification regarding unquoted securities - ATX
- Results of Annual General Meeting
- CEO Managing Director Presentation to Annual General Meeting
- Bioshares Biotech Summit Presentation
- Amplia signs Collaboration and Supply Agreement with Lilly
Later from Amplia Therapeutics
- Amplia Presents at E&P Healthcare Conference 2026
- Amplia Presents at CG Drug and Device Conference 2026
- Response to ASX Price Query
- Amplia Therapeutics Provides Clinical Trial Updates
- Amplia Receives R&D Tax Rebate Totalling $4.78 Million
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics